DAROL: RW study of darolutamide in nmCRPC (n=550) - 3rd interim analysis
🔷Safety consistent with ARAMIS: Any grade 38%; Serious 10.2%, Leading to d/c 6.4%
Most common: fatigue (8.7%), rash (1.6%), falls (1.5%)
🔷Efficacy: Median OS, MS, PSA-PFS not reached yet
2 year OS: 88%, 2

nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives

🔹Apalutamide, enzalutamide or darolutamide plus ADT➡️ MFS and OS⬆️

A great review of the efficacy and safety of these drugs👇

#cancertreatmentreview cancertreatmentreviews.com/article/S0305-…

Today an update on a rare and challenging setting of patients #nmCRPC

Do we have nmCRPC at PSMA era?

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET) Disease Extent and Overall Survival in Patients With High-Risk Nonmetastatic Castration-Resistant Prostate Cancer: an International Multicenter Retrospective Study:

Analysis of 200 nmCRPC pts undergoing PSMA-PET (SPARTAN/PROSPER/ARAMIS-like cohort):
🔷Median OS: 6 yrs (same as APA arm in SPARTAN)
🔷 PET-detected polymets (5+ lesions) ⬇️ OS (HR=1.8; p=0.024) & ⬇️ new metastases-free survival (median 38 vs 60 months, p=0.02)
UroToday.com #ASCO23

Managing mHSPC and nmCRPC: Get expert insight in a new CE OnDemand from Madrid
#PeerVoice #meded #oncology #urology #prostatecancer

peervoice.com/HHV?PromoCode=…

DEAR Study: Real world use of Daro, Enza, Apa for nmCRPC using 🇺🇸 urology practice data
n=666 pts, median f/u ~23 months
🚩Lower rate of tx d/c with daro (28%) vs enza (38%) & apa (46%)
🚩⬇️ mCRPC progression for daro (18%) vs enza (29%) & apa (26%)
UroToday.com #AUA23

ARAMIS secondary analysis: ⬆️ HRQoL & urinary/bowel symptoms in nmCRPC pts with better PSA responses to darolutamide
🔷3-yr deterioration-free survival rates for urinary & bowel symptoms:
- PSA90: 38% and 34%
- PSA50-90: 31% and 17%
- PSA50: 15% and 13%
UroToday.com #ESMO23

DAROL: Real-world study of darolutamide in nmCRPC pts (n=300)
🔷Any grade darolutamide-related TEAE: 24% (most common: fatigue 8%)
🔷Gr 3-4 AEs: 4%
🔷Safety profile similar to that observed in ARAMIS
🚩PSA50: 76%, PSA90: 54% (other efficacy endpoints pending)
UroToday.com #ASCO23

Phase II trial of anti-PSMA mAB J591 labelling w/ 177Lu vs 111In in nmCRPC
🚩18-mo MFS (1 outcome): 50% w/ 177Lu vs 24% with 111In
🚩PSA50: 82 vs 71%
🚩PSA90: 50 vs 35%
⬆️Heme toxicity with 177Lu (neutropenia 57 vs 11%; thrombocytopenia 77 vs 11%)
#GU23 UroToday.com

GU ASCO 23: PCa Poster Session
Race association with nmCRPC to mCRPC progression
🔷13K nmCRPC VA pts
🚩Within equal opportunity/access system:
-AA race (vs W) HR for progression: 0.85 (p<0.001)
-Hispanic (vs W) HR for progression: 0.70 (p<0.001)
#GU23 UroToday.com

Time for nmCRPC at #PROSCA23 by Alberto Bossi
📍PETPSMA is useful for demostrating mCRPC, however it is not routinately performed
📍it remains unclear ir the use of PETPSMA in this setting improves outcome
📍Daro/Apa/Enza demostrate ⬆️MFS and OS in PSADT<10 m
📍Consider

Well done to our colleagues for excellent presentations on updates on nmCRPC management and treatment Olivia finn Margaret Burke delivered a holistic view of exploring survivorship with their research 'Smitten' well done everyone 🎉 Maura Heffernan Olive Gallagher NCCP

➡️ Polymetastases (5+) on #PSMA -PET + initial pN1 status are associated with shorter OS #nmCRPC
➡️ PSMA-PET disease extent results in additional risk stratification European Urology
Thank you for integrating me in this great collaboration #WolfgangFendler #ManuelWeber 👇

Accepted!
Real-world effects of novel ARSI on oncological outcomes in nmCRPC

nmCRPCに対するARSIの有効性についてリアルワールドで検討した報告

Key findings

1, PSA-DT< 3mo.とARSI使用がMFSとOSに有意に相関

2, ARSIは予後不良因子(PSADT<3mo., GS>9-10, T4/N+にかかわらず有効

Can combining flutamide & PROSTVAC improve outcomes in nmCRPC patients? 💉

📌 Study findings:
📌Multicenter, randomized trial
📌Flutamide alone vs. Flutamide+PROSTVAC
📌No significant improvement with combo (p=0.38)
📌Similar antigen-specific responses
The Oncologist OncoAlert

Back in the trenches, discussing our poster on #RWD for Daro, Enzo and Apa in men with nmCRPC. Median age 80 and 22% Black men. Less D/C or progression on Daro, but independent validation is needed. ⁦⁦Alicia Morgans, MD, MPH⁩

📊 In the APCCC 2022, experts weighed in on a crucial consensus question for nmCRPC treatment:

🔍 Consensus Question 111: For asymptomatic patients with nmCRPC, PSA doubling time ≤10 months, and confirmed local progression without prior radical treatment—what's your

Provocative work by ⁦Scott Tagawa⁩ with radiopharmaceutical therapy in nmCRPC. With cautious dosing perhaps these agents can be moved to micro metastatic setting

Published!
nmCRPCに対する新規ARSIのリアルワールドデータ

Effects of novel ARSI on nmCRPC: A Real-world data
sciencedirect.com/science/articl…